FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027543203> ?p ?o ?g. }

• W2027543203 endingPage "2588" @default.
• W2027543203 startingPage "2576" @default.
• W2027543203 abstract "Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B.In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudine once daily. The primary efficacy end point was noninferiority of telbivudine to lamivudine for therapeutic response (i.e., a reduction in serum HBV DNA levels to fewer than 5 log10 copies per milliliter, along with loss of hepatitis B e antigen [HBeAg] or normalization of alanine aminotransferase levels). Secondary efficacy measures included histologic response, changes in serum HBV DNA levels, and HBeAg responses.At week 52, a significantly higher proportion of HBeAg-positive patients receiving telbivudine than of those receiving lamivudine had a therapeutic response (75.3% vs. 67.0%, P=0.005) or a histologic response (64.7% vs. 56.3%, P=0.01); telbivudine also was not inferior to lamivudine for these end points in HBeAg-negative patients. In HBeAg-positive and HBeAg-negative patients, telbivudine was superior to lamivudine with respect to the mean reduction in the number of copies of HBV DNA from baseline, the proportion of patients with a reduction in HBV DNA to levels undetectable by polymerase-chain-reaction assay, and development of resistance to the drug. Elevated creatine kinase levels were more common in patients who received telbivudine, whereas elevated alanine aminotransferase and aspartate aminotransferase levels were more common in those who received lamivudine.Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic and histologic response at 1 year were significantly higher in patients treated with telbivudine than in patients treated with lamivudine. In both the HBeAg-negative and the HBeAg-positive groups, telbivudine demonstrated greater HBV DNA suppression with less resistance than did lamivudine. (ClinicalTrials.gov number, NCT00057265 [ClinicalTrials.gov].)." @default.
• W2027543203 created "2016-06-24" @default.
• W2027543203 creator A5000208156 @default.
• W2027543203 creator A5007003624 @default.
• W2027543203 creator A5007668416 @default.
• W2027543203 creator A5022731052 @default.
• W2027543203 creator A5024470010 @default.
• W2027543203 creator A5029727529 @default.
• W2027543203 creator A5034128734 @default.
• W2027543203 creator A5038545834 @default.
• W2027543203 creator A5042155617 @default.
• W2027543203 creator A5045392886 @default.
• W2027543203 creator A5045504446 @default.
• W2027543203 creator A5050985880 @default.
• W2027543203 creator A5064143989 @default.
• W2027543203 creator A5068309561 @default.
• W2027543203 creator A5080891683 @default.
• W2027543203 creator A5086142040 @default.
• W2027543203 creator A5088842832 @default.
• W2027543203 creator A5091803938 @default.
• W2027543203 date "2007-12-20" @default.
• W2027543203 modified "2023-10-18" @default.
• W2027543203 title "Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B" @default.
• W2027543203 cites W133318803 @default.
• W2027543203 cites W1643958559 @default.
• W2027543203 cites W1975882243 @default.
• W2027543203 cites W1977202875 @default.
• W2027543203 cites W1977281708 @default.
• W2027543203 cites W1978009452 @default.
• W2027543203 cites W1981900811 @default.
• W2027543203 cites W1985860298 @default.
• W2027543203 cites W1996615534 @default.
• W2027543203 cites W2000804430 @default.
• W2027543203 cites W2004054613 @default.
• W2027543203 cites W2008517556 @default.
• W2027543203 cites W2009944703 @default.
• W2027543203 cites W2014837723 @default.
• W2027543203 cites W2040289109 @default.
• W2027543203 cites W2042329639 @default.
• W2027543203 cites W2045800657 @default.
• W2027543203 cites W2055205839 @default.
• W2027543203 cites W2071291950 @default.
• W2027543203 cites W2076506726 @default.
• W2027543203 cites W2084044317 @default.
• W2027543203 cites W2091726543 @default.
• W2027543203 cites W2097754581 @default.
• W2027543203 cites W2104389844 @default.
• W2027543203 cites W2106667426 @default.
• W2027543203 cites W2107328434 @default.
• W2027543203 cites W2108147025 @default.
• W2027543203 cites W2115956200 @default.
• W2027543203 cites W2122070481 @default.
• W2027543203 cites W2123543307 @default.
• W2027543203 cites W2140415000 @default.
• W2027543203 cites W2156015715 @default.
• W2027543203 cites W2161280033 @default.
• W2027543203 cites W2166826446 @default.
• W2027543203 cites W2169631718 @default.
• W2027543203 cites W2170244859 @default.
• W2027543203 cites W2293495463 @default.
• W2027543203 cites W2335360980 @default.
• W2027543203 cites W2341203768 @default.
• W2027543203 cites W2393327590 @default.
• W2027543203 cites W4231124841 @default.
• W2027543203 doi "https://doi.org/10.1056/nejmoa066422" @default.
• W2027543203 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18094378" @default.
• W2027543203 hasPublicationYear "2007" @default.
• W2027543203 type Work @default.
• W2027543203 sameAs 2027543203 @default.
• W2027543203 citedByCount "722" @default.
• W2027543203 countsByYear W20275432032012 @default.
• W2027543203 countsByYear W20275432032013 @default.
• W2027543203 countsByYear W20275432032014 @default.
• W2027543203 countsByYear W20275432032015 @default.
• W2027543203 countsByYear W20275432032016 @default.
• W2027543203 countsByYear W20275432032017 @default.
• W2027543203 countsByYear W20275432032018 @default.
• W2027543203 countsByYear W20275432032019 @default.
• W2027543203 countsByYear W20275432032020 @default.
• W2027543203 countsByYear W20275432032021 @default.
• W2027543203 countsByYear W20275432032022 @default.
• W2027543203 countsByYear W20275432032023 @default.
• W2027543203 crossrefType "journal-article" @default.
• W2027543203 hasAuthorship W2027543203A5000208156 @default.
• W2027543203 hasAuthorship W2027543203A5007003624 @default.
• W2027543203 hasAuthorship W2027543203A5007668416 @default.
• W2027543203 hasAuthorship W2027543203A5022731052 @default.
• W2027543203 hasAuthorship W2027543203A5024470010 @default.
• W2027543203 hasAuthorship W2027543203A5029727529 @default.
• W2027543203 hasAuthorship W2027543203A5034128734 @default.
• W2027543203 hasAuthorship W2027543203A5038545834 @default.
• W2027543203 hasAuthorship W2027543203A5042155617 @default.
• W2027543203 hasAuthorship W2027543203A5045392886 @default.
• W2027543203 hasAuthorship W2027543203A5045504446 @default.
• W2027543203 hasAuthorship W2027543203A5050985880 @default.
• W2027543203 hasAuthorship W2027543203A5064143989 @default.
• W2027543203 hasAuthorship W2027543203A5068309561 @default.
• W2027543203 hasAuthorship W2027543203A5080891683 @default.

• next